1. Home
  2. IMCR vs AMPH Comparison

IMCR vs AMPH Comparison

Compare IMCR & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • AMPH
  • Stock Information
  • Founded
  • IMCR 2008
  • AMPH 1996
  • Country
  • IMCR United Kingdom
  • AMPH United States
  • Employees
  • IMCR N/A
  • AMPH N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • AMPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMCR Health Care
  • AMPH Health Care
  • Exchange
  • IMCR Nasdaq
  • AMPH Nasdaq
  • Market Cap
  • IMCR 1.5B
  • AMPH 1.1B
  • IPO Year
  • IMCR 2021
  • AMPH 2014
  • Fundamental
  • Price
  • IMCR $32.80
  • AMPH $23.20
  • Analyst Decision
  • IMCR Buy
  • AMPH Hold
  • Analyst Count
  • IMCR 10
  • AMPH 5
  • Target Price
  • IMCR $58.13
  • AMPH $38.00
  • AVG Volume (30 Days)
  • IMCR 444.9K
  • AMPH 493.6K
  • Earning Date
  • IMCR 08-07-2025
  • AMPH 08-06-2025
  • Dividend Yield
  • IMCR N/A
  • AMPH N/A
  • EPS Growth
  • IMCR N/A
  • AMPH N/A
  • EPS
  • IMCR N/A
  • AMPH 2.77
  • Revenue
  • IMCR $333,581,000.00
  • AMPH $730,659,000.00
  • Revenue This Year
  • IMCR $26.82
  • AMPH $0.67
  • Revenue Next Year
  • IMCR $8.15
  • AMPH $5.18
  • P/E Ratio
  • IMCR N/A
  • AMPH $8.39
  • Revenue Growth
  • IMCR 25.75
  • AMPH 8.05
  • 52 Week Low
  • IMCR $23.15
  • AMPH $22.64
  • 52 Week High
  • IMCR $41.54
  • AMPH $53.96
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 51.47
  • AMPH 37.07
  • Support Level
  • IMCR $30.76
  • AMPH $22.81
  • Resistance Level
  • IMCR $33.95
  • AMPH $24.52
  • Average True Range (ATR)
  • IMCR 1.39
  • AMPH 0.74
  • MACD
  • IMCR -0.15
  • AMPH -0.22
  • Stochastic Oscillator
  • IMCR 43.05
  • AMPH 11.27

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: